

Adamantanes as building blocks for novel TRPC5 channel modulators





Holger Beckmann & Michael Schaefer
Rudolf-Boehm-Institute for Pharmacology and Toxicology, Leipzig University

Introduction


The transient receptor potential (TRP) channels are a family of non-selective cation channels, comprising 28 members in mammals. They are involved in a plethora of physiological and pathophysiological processes [1]. Among these, the canonical TRP channel 5 (TRPC5) is almost exclusively found in neuronal tissues. TRPC5 is involved in neuronal plasticity and axonal pathfinding in hippocampal neurons and has been shown to influence the formation of memory [2,3]. Furthermore, TRPC5 may interfere with the reproductive axis in rodents. TRPC5-deficient transgenic animals show impaired motor coordination and reduced fear behavior [4,5,6]. In the past years, intensive research aimed at identifying novel small molecules to enable precise pharmacological modulation of TRPC5 channels.

Key findings


The screening of a compound library containing almost 17,000 different chemical structures revealed seven small molecules that modulate TRPC5 channel activity. These diverse chemical structures all share adamantane-substituents and acted either as channel activators or channel inhibitors. Adamantanes without prominent side chains were selective, but poorly potent inhibitors of TRPC5 and TRPC4 channels (IC_{50} of 3-10 μ M), while those with bigger substitutions tend to be activators (EC_{50} of 0.7-5 μ M) or mixed activators/inhibitors. We aim at clarifying adamantane effects on TRPC5 channels to eventually promote the development of ready-to-use small molecules to treat TRPC5-associated disorders.




Fluorometric Ca^{2+} assay in TRPC5 overexpressing HEK293 cells (HEK_{TRPC5}). Fluo-4-loaded cells (A-B) or Fura-2-loaded cells (C) were treated with different concentrations of **A1** as well as established TRPC5 inhibitors as indicated.




Fluorometric Ca^{2+} assay in TRPC5 overexpressing HEK293 cells (HEK_{TRPC5}). Fluo-4-loaded cells (A-B) or Fura-2-loaded cells (C) were treated with different concentrations of **B1** as well as established TRPC5 activators as indicated.




Fluorometric Ca^{2+} assay in TRPC5 overexpressing HEK293 cells (HEK_{TRPC5}). Fluo-4-loaded cells (A-B) or Fura-2-loaded cells (C) were treated with different concentrations of **B2** as well as established TRPC5 activators as indicated.




Electrophysiological recordings of TRPC5 currents in whole cell (A) or inside-out (B) configurations. Cells or membrane patches were treated with 10 μ M **A1** as indicated. **A1** elicits TRPC5-like currents.




Electrophysiological recordings of HEK_{TRPC5} cells in the whole cell configuration. Cells were activated either with 10 μ M **A1** or by change in pH as indicated in the inset. Inhibition was achieved by applying 10 μ M **B1**.




Electrophysiological recordings of HEK_{TRPC5} cells in the whole cell configuration. Cells were activated either with 10 μ M **A1** or by change in pH as indicated in the inset. Inhibition was achieved by applying 20 μ M **B2**.



Fluorometric Ca^{2+} assay with HEK293 cells that stably express various TRP channels. Cells were treated with 100 μ M of **A1** or a respective channel activator as indicated.




Fluorometric Ca^{2+} assay with HEK293 cells that stably express various TRP channels. Cells were treated with 100 μ M of **B1** and respective channel activators as indicated.




Fluorometric Ca^{2+} assay with HEK293 cells that stably express various TRP channel. Cells were treated with 100 μ M of **B2** and respective channel activators as indicated.

1 change in the channel surrounding



2 direct channel interaction



3 interaction with mechanisms upstream of the channel

